Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
eFBRptPnEat5FLDy
